科研成果详情

题名Efficacy and safety of CalliSpheres (R) drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC study
作者
发表日期2019-08
发表期刊TRANSLATIONAL CANCER RESEARCH   影响因子和分区
语种英语
原始文献类型Article
关键词Drug-eluting beads transarterial chemoembolization (DEB-TACE) secondary liver cancer treatment response overall survival liver function safety
其他关键词HEPATOCELLULAR-CARCINOMA ; METASTASIS ; MICROSPHERES
摘要Background: This study aimed to assess the treatment response, short-term overall survival (OS) and safety profiles of drug-eluting beads transarterial chemoembolization (DEB-TACE) in patients with secondary liver cancer. Methods: Fifty-five patients with secondary liver cancer underwent DEB-TACE were enrolled in this prospective cohort study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST). OS was calculated from the time of DEB-TACE operation until the date of death. Results: The complete response (CR) and objective response rate (ORR) at 1-3 months post DEB-TACE were 12.7% and 67.3 %. Mean OS was 383 d (95% CI: 360-406), and 6-month OS rate was 93.4%+/- 3.7%. Subgroup analysis revealed previous conventional TACE (cTACE) treatment was correlated with worse ORR (P=0.028), and it was a risk factor for ORR achievement (P=0.021). As for liver function, the percentages of abnormal TP (P=0.031), TBIL (P=0.022), ALT (P=0.002) and AST (P=0.035) were increased at 1 week post DEB-TACE compared to baseline, while these four indexes returned to baseline (all P>0.05) at 1-3 months post DEB-TACE. As to safety profiles, 41 (66.1%), 28 (45.2%), 17 (27.4%), 8 (12.9%) and 6 (9.7%) cases had pain, vomiting, fever, nausea and other adverse events (AEs) respectively during DEB-TACE operation, while 26 (41.9%), 9 (14.5%), 8 (12.9%), 4 (6.5%), 1 (1.6%) and 2 (3.2%) cases had pain, fever, vomiting, nausea, bone marrow toxicity and other AEs respectively at 1 month after DEB-TACE operation. Conclusions: DEB-TACE was efficient and well tolerated in treating patients with secondary liver cancer.
资助项目National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371658]; Zhejiang Provincial Natural Science FoundationNatural Science Foundation of Zhejiang Province [LZ18H180001, LY18H180002]; Medical Health Science and Technology Project of Zhejiang Provincial Health Commission [2016151760]
出版者AME PUBL CO
出版地SHATIN
ISSN2218-676X
EISSN2219-6803
卷号8期号:4页码:1199-1216
DOI10.21037/tcr.2019.06.44
页数18
WOS类目Oncology
WOS研究方向Oncology
WOS记录号WOS:000484233000019
收录类别SCIE ; PUBMED ; SCOPUS
URL查看原文
PubMed ID35116862
PMC记录号PMC8797412
SCOPUSEID2-s2.0-85073024689
通讯作者地址[Hu, Hongjie]Department of Radiology,Sir Run Run Shaw Hospital,Zhejiang University College of Medicine,3 Qingchun East Road,Hangzhou,310016,China
Scopus学科分类Oncology;Radiology, Nuclear Medicine and Imaging;Cancer Research
引用统计
被引频次[WOS]:0   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/20694
专题其他_附属第三医院(瑞安市人民医院)
附属第一医院
其他_附属第五医院(丽水市中心医院)
通讯作者Hu, Hongjie
作者单位
1.Department of Radiology,Sir Run Run Shaw Hospital,Zhejiang University College of Medicine,3 Qingchun East Road,Hangzhou,310016,China;
2.Department of Radiology,First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou,310003,China;
3.Department of Hepatobiliary Surgery,Ningbo Medical Center,Lihuili Eastern Hospital,Ningbo,315040,China;
4.Department of Intervention,Third Affiliated Hospital of Wenzhou Medical University,Ruian,325200,China;
5.Department of Radiology,Lishui Central Hospital,Lishui Hospital of Zhejiang University,Fifth Affiliated Hospital of Wenzhou Medical University,Lishui,323000,China;
6.Hepatobiliary and Pancreatic Interventional Treatment Center,Division of Hepatobiliary and Pancreatic Surgery,First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,310003,China;
7.Department of Radiology,First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou,310006,China;
8.Department of Intervention,Zhejiang Provincial People’s Hospital,Hangzhou,310014,China;
9.Department of Intervention,First Affiliated Hospital of Wenzhou Medical University,Wenzhou,325000,China;
10.Department of Radiology,Hangzhou Cancer Hospital,Hangzhou,310002,China;
11.Department of Intervention,Zhejiang Cancer Hospital,Hangzhou,310022,China;
12.Department of Vascular and Interventional Radiology,Affiliated Hospital of Medical College of Ningbo University,Ningbo,315020,China;
13.Department of Radiology,Xixi Hospital of Hangzhou,Hangzhou 6th People’s Hospital,Hangzhou,310023,China;
14.Department of Intervention,Jiaxing Second Hospital,Jiaxing,314099,China;
15.Department of Radiology,Beilun District People’s Hospital of Ningbo,Ningbo,315800,China;
16.Interventional Center,Xinchang People’s Hospital,Shaoxing,312500,China;
17.Department of Radiology,Shulan (Hangzhou) Hospital,Zhejiang University International Hospital,Hangzhou,310000,China;
18.Department of Intervention,Dong Yang People’s Hospital,Dongyang,322100,China;
19.Department of Liver Oncology,Ningbo No.2 Hospital,Ningbo,315010,China;
20.Division of Digestive Endoscopy,Yueqing City People’s Hospital,Yueqing,325600,China;
21.Department of Intervention,Jiaxing First Hospital,Jiaxing,314033,China;
22.Department of Radiology,Taizhou Hospital of Zhejiang Province,Linhai,317000,China;
23.Department of Hepatobiliary Surgery,Quzhou People’s Hospital,Quzhou,324000,China;
24.Department of Intervention,Jinhua Central Hospital,351 Mingyue Street,Jinhua,321000,China
推荐引用方式
GB/T 7714
Wu, Xia,Ying, Shihong,Huang, Jing,et al. Efficacy and safety of CalliSpheres (R) drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC study[J]. TRANSLATIONAL CANCER RESEARCH,2019,8(4):1199-1216.
APA Wu, Xia., Ying, Shihong., Huang, Jing., Shi, Changsheng., Ji, Jiansong., ... & Guo, Xiaohua. (2019). Efficacy and safety of CalliSpheres (R) drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC study. TRANSLATIONAL CANCER RESEARCH, 8(4), 1199-1216.
MLA Wu, Xia,et al."Efficacy and safety of CalliSpheres (R) drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC study".TRANSLATIONAL CANCER RESEARCH 8.4(2019):1199-1216.

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Wu, Xia]的文章
[Ying, Shihong]的文章
[Huang, Jing]的文章
百度学术
百度学术中相似的文章
[Wu, Xia]的文章
[Ying, Shihong]的文章
[Huang, Jing]的文章
必应学术
必应学术中相似的文章
[Wu, Xia]的文章
[Ying, Shihong]的文章
[Huang, Jing]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。